TherapeuticsMD Inc (NASDAQ:TXMD) CEO Robert G. Finizio sold 184,000 shares of TherapeuticsMD stock in a transaction that occurred on Friday, October 26th. The stock was sold at an average price of $5.28, for a total value of $971,520.00. Following the completion of the transaction, the chief executive officer now owns 18,485,559 shares of the company’s stock, valued at approximately $97,603,751.52. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
TXMD opened at $4.94 on Wednesday. TherapeuticsMD Inc has a 52-week low of $4.30 and a 52-week high of $7.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 7.88 and a quick ratio of 7.79. The firm has a market cap of $1.18 billion, a P/E ratio of -13.35 and a beta of 1.40.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Monday, July 30th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03). TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. The business had revenue of $3.80 million for the quarter, compared to analysts’ expectations of $4.23 million. During the same quarter in the previous year, the firm earned ($0.10) EPS. TherapeuticsMD’s revenue was down 11.6% compared to the same quarter last year. As a group, research analysts forecast that TherapeuticsMD Inc will post -0.63 earnings per share for the current fiscal year.
A number of research firms recently issued reports on TXMD. ValuEngine cut TherapeuticsMD from a “buy” rating to a “hold” rating in a report on Saturday, July 28th. Zacks Investment Research upgraded TherapeuticsMD from a “hold” rating to a “buy” rating and set a $6.25 price objective for the company in a report on Wednesday, October 17th. Cantor Fitzgerald set a $27.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a report on Sunday, October 14th. BidaskClub cut TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Tuesday, July 3rd. Finally, Oppenheimer set a $14.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a report on Monday, August 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $13.88.
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Featured Story: Using the New Google Finance Tool
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.